Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors

Esteban Braggio, Danielle De Almeida Braggio, Isabele Ávila Small, Lisandro F. Lopes, Marcus Valadão, Maria Emmerick Gouveia, Aline Dos Santos Moreira, Eduardo Linhares, Sérgio Romano, Carlos E. Bacchi, Ilana Zalcberg Renault, Denise Peixoto Guimarães, Carlos Gil Ferreira

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Background: Prediction of biological behavior is crucial for selection of new therapeutic modalities in GIST. Here, we aimed to assess whether KIT and PDGFRA mutations have survival impact in gastrointestinal stromal tumors (GIST). Patients and Methods: Fifty-five Brazilian patients with completely resected GIST were examined for KIT and PDGFRA mutations. The 5-year disease-free survival (DFS) was analyzed. Results: KIT and PDGFRA mutations were identified in 74.5% and 7.3% of patients, respectively. The 5-year DFS rate for all patients was 52.8%. The 5-year DFS rate was lower in patients with tumors having inframe deletions or concomitant in-frame deletions and insertions affecting codons 557-558 than in patients with tumors having other exon 11 KIT mutations (p=0.023). Conversely, when the patients with concomitant deletion-insertion mutations affecting codons 557-558 were excluded from the analysis, deletions involving codons 557-558 had no influence on 5-year DFS rates. Conclusion: Our findings indicate that a specific KIT mutation may be associated with unfavorable behavior in GIST. This finding may have implications on selecting patients for adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)2407-2414
Number of pages8
JournalAnticancer research
Issue number6
StatePublished - Jun 2010


  • GIST
  • KIT
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors'. Together they form a unique fingerprint.

Cite this